Nonprofit Sing Me a Story and Numotion are collaborating to help children with various neuromuscular diseases served by the Muscular Dystrophy Association (MDA) share their unique stories through song. This alliance was supported by the ongoing partnership between MDA and Numotion, a company that provides mobility products and services.
Pfizer is halting the clinical development of domagrozumab (PF-06252616) as treatment for Duchenne muscular dystrophy (DMD) in an ongoing Phase 2 trial. The latest trial data failed to demonstrate domagrozumab’s potential to prevent disease progression or improve patient’s physical capacity, as assessed by mean changes (in seconds) from…
With an emphasis on standards of care, groups such as the Parent Project Muscular Dystrophy and the Jett Foundation are gearing up for Sept. 7, World Duchenne Awareness Day (WDAD) 2018. Organizations are recommending a host of ways to raise awareness for Duchenne muscular dystrophy,…
The Pacific Northwest chapter of the FSH Society is holding its first-ever “Walk & Roll to Cure FSHD” event Sept. 22 in Puyallup, Washington, a small city about 35 miles south of Seattle. FSH Society holds these events around the U.S., with the goal of raising funds for its work…
For both children and adults with Duchenne or Becker muscular dystrophy, having a specially trained dog doesn’t just relieve their loneliness. These service dogs also help patients in dozens of practical ways, doing everything from taking off shoes to picking up toys that fall on the floor. Tali…
The Muscular Dystrophy Association (MDA) has awarded a total of $9.9 million to 34 pioneering and innovative projects worldwide in its continuing efforts to support groundbreaking research for more than 40 neuromuscular diseases. “This latest round of grants is impressive in terms of total funding, number of grants awarded…
AbCellera Biologics Inc. has announced a collaboration with Fabio Rossi, MD, PhD, and Michael Underhill, PhD, of the University of British Columbia, to develop therapeutic antibodies for the treatment of Duchenne muscular dystrophy-associated fibrosis. “It is immensely satisfying to see many years of…
Boys with Duchenne muscular dystrophy (DMD) on a long-term daily regimen of glucocorticoids are more likely to develop spinal fractures, have poorer growth and gain more body fat, than do those on intermittent use, a two-year study reports. But study findings also suggest that those…
Caring for a son with Duchenne muscular dystrophy is hard enough. Imagine how much harder it is when you’ve lost your other son to the same disease. That’s the uncertainty DeAnne Friar of Grand Rapids, Michigan, lives with day after day. Her first child, 20-year-old Colleen, attends Western Michigan University…
Wave Life Sciences’ treatment candidate WVE-210201 has been granted both orphan drug designation and rare pediatric disease designation for the treatment of Duchenne muscular dystrophy (DMD) from the U.S. Food and Drug Administration. Orphan drug designation provides Wave with seven years of market exclusivity in the U.S., tax…
Get regular updates to your inbox.